E. de Kermadec

[Vitamin D and cancers].

M. Espié, F. Coussy, J. Wassermann, 2013, Presse medicale.

Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).

J. Varinot, I. Thomassin-Naggara, N. Chabbert-Buffet, 2021, Gynecologic oncology.

212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)

P. Kaufman, K. Petráková, G. Paux, 2022, Annals of Oncology.

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

H. Iwata, N. Ternès, M. Campone, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.